Aspire Biopharma (ASBP) Competitors $0.36 +0.01 (+1.42%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASBP vs. ATYR, ARTV, CVM, ABVC, BYSI, QNTM, VNRX, GANX, INKT, and NRXPShould you be buying Aspire Biopharma stock or one of its competitors? The main competitors of Aspire Biopharma include aTyr Pharma (ATYR), Artiva Biotherapeutics (ARTV), CEL-SCI (CVM), ABVC BioPharma (ABVC), BeyondSpring (BYSI), Quantum Biopharma (QNTM), VolitionRx (VNRX), Gain Therapeutics (GANX), MiNK Therapeutics (INKT), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical products" industry. Aspire Biopharma vs. Its Competitors aTyr Pharma Artiva Biotherapeutics CEL-SCI ABVC BioPharma BeyondSpring Quantum Biopharma VolitionRx Gain Therapeutics MiNK Therapeutics NRx Pharmaceuticals aTyr Pharma (NASDAQ:ATYR) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Do analysts recommend ATYR or ASBP? aTyr Pharma currently has a consensus target price of $23.25, suggesting a potential upside of 2,225.00%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Aspire Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable earnings & valuation, ATYR or ASBP? Aspire Biopharma has lower revenue, but higher earnings than aTyr Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr Pharma$230K426.04-$64.02M-$0.80-1.25Aspire BiopharmaN/AN/A-$12.54MN/AN/A Does the media favor ATYR or ASBP? In the previous week, aTyr Pharma had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 6 mentions for aTyr Pharma and 4 mentions for Aspire Biopharma. aTyr Pharma's average media sentiment score of 0.22 beat Aspire Biopharma's score of 0.17 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aspire Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ATYR or ASBP more profitable? Aspire Biopharma's return on equity of 0.00% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -93.69% -68.83% Aspire Biopharma N/A N/A -737.96% Which has more risk & volatility, ATYR or ASBP? aTyr Pharma has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Aspire Biopharma has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ATYR or ASBP? 61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by company insiders. Comparatively, 25.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryaTyr Pharma beats Aspire Biopharma on 9 of the 12 factors compared between the two stocks. Get Aspire Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASBP vs. The Competition Export to ExcelMetricAspire BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.04M$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E RatioN/A21.7185.5527.59Price / SalesN/A477.39622.26138.47Price / CashN/A47.6737.7861.77Price / Book-0.1710.1413.136.76Net Income-$12.54M-$52.31M$3.30B$275.88M7 Day Performance69.76%6.72%5.27%3.71%1 Month Performance-28.81%15.01%9.93%10.21%1 Year PerformanceN/A29.34%87.76%35.85% Aspire Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASBPAspire BiopharmaN/A$0.36+1.4%N/AN/A$18.04MN/A0.00N/AAnalyst ForecastGap DownATYRaTyr Pharma2.8658 of 5 stars$0.78+9.2%$23.25+2,899.2%-55.8%$75.96M$230K0.0053Analyst ForecastARTVArtiva Biotherapeutics3.3907 of 5 stars$2.95flat$17.00+476.3%-80.0%$72.06M$250K0.0081News CoveragePositive NewsAnalyst ForecastCVMCEL-SCIN/A$10.47+3.1%N/AN/A$72.06MN/A-21.8143ABVCABVC BioPharma0.9198 of 5 stars$3.00-0.7%N/A+484.9%$70.63M$510K0.0030News CoverageAnalyst ForecastBYSIBeyondSpringN/A$1.75+1.2%N/A-23.3%$70.58M$1.75M0.0080Positive NewsAnalyst ForecastQNTMQuantum Biopharma0.5033 of 5 stars$18.45+1.9%N/A+307.1%$70.40MN/A0.00N/ANews CoverageAnalyst ForecastVNRXVolitionRx2.4433 of 5 stars$0.65+3.6%$3.50+440.1%-17.2%$69.72M$1.32M-1.8080GANXGain Therapeutics3.0494 of 5 stars$1.92+3.2%$8.00+316.7%-5.4%$69.02M$50K-3.0520News CoverageAnalyst ForecastOptions VolumeGap UpINKTMiNK Therapeutics2.6174 of 5 stars$15.02-2.8%$37.50+149.7%+109.8%$67.91MN/A-5.2230Analyst ForecastGap DownNRXPNRx Pharmaceuticals3.069 of 5 stars$3.27-1.8%$34.50+955.0%+144.7%$64.78MN/A-1.462Analyst Forecast Related Companies and Tools Related Companies ATYR Alternatives ARTV Alternatives CVM Alternatives ABVC Alternatives BYSI Alternatives QNTM Alternatives VNRX Alternatives GANX Alternatives INKT Alternatives NRXP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASBP) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
